硫酸沙丁胺醇(Salbutamol sulfate) - 药物靶点：β2-adrenergic receptor_在研适应症：运动诱发哮喘，支气管痉挛，气道阻塞_专利_临床

概要

基本信息

药物类型

小分子化药

别名

ALBUTEROL、ALBUTEROL SULFATE、Salbutamol

+ [53]

靶点

β2-adrenergic receptor

作用机制

β2-adrenergic receptor激动剂(β2-肾上腺素能受体激动剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

GlaxoSmithKline Intellectual Property Ltd.

GSK PlcTeva Branded Pharmaceutical Products R&D, Inc.

+ [4]

非在研机构

Schering Corp.

Boehringer Ingelheim GmbHMylan Pharmaceuticals, Inc.

+ [1]

最高研发阶段批准上市

首次获批日期

日本 (1973-01-13),

气道阻塞哮喘支气管炎+ [2]

最高研发阶段(中国)批准上市

特殊审评孤儿药 (美国)

登录后查看时间轴

结构

分子式C13H23NO7S

InChIKeyOVICLFZZVQVVFT-UHFFFAOYSA-N

CAS号51022-70-9

关联

429

项与硫酸沙丁胺醇相关的临床试验

CTRI/2024/10/075854 / Not yet recruitingN/AIIT

Evaluation of comparative efficacy of inhalation of Dugdhika (Euphorbia prostrata w. Ait) versus Salbutamol in the management of Tamaka Shwasa(Bronchial asthma) – A Randomized Controlled Trial. - NIL

开始日期2024-12-27

申办/合作机构-

CTRI/2024/11/076181 / Not yet recruitingN/A

A Prospective, Randomized, Single-dose, Double-blind, Double-dummy, Four-period, Four-treatment Crossover Pivotal Bronchoprovocation Study to Demonstrate the Pharmacodynamic Bioequivalence of Albuterol sulfate HFA Inhalation Aerosol (E.Q. 90 mcg of albuterol Base/Inh) (of Macleods Pharmaceuticals Ltd.) to Albuterol sulfate HFA Inhalation Aerosol (E.Q. 90 mcg of albuterol Base/Inh) (distributed by Teva Pharmaceuticals USA, Inc.) in Adult Patients with Stable Mild Asthma. - NIL

开始日期2024-11-05

申办/合作机构-

NCT06426082 / Not yet recruitingN/AIIT

Deciphering the Molecular and Secretory Functions of a Novel and Unique Brown Adipose Tissue Depot in Women

Type of Study: Clinical Trial
Goal: The goal of this clinical trial is to investigate specific brown and beige fat cells in the dorsocervical area of young, lean adult women.
Participant Population/Health Conditions: The study will involve 40 young, lean adult women.
Main Questions: The main questions this study aims to answer are:
Are there active brown or beige adipocytes in the subcutaneous fat of the dorsocervical area (i.e., iBAT)?
What is the secretory function of these adipocytes?
How do traditional interventions like cold exposure, as well as new approaches like Beta-2 agonist stimulation and exercise, affect the thermogenesis of these fat cells at the cellular and molecular levels?
Participants Will:
Be randomized into one of four groups: thermoneutral exposure, cold exposure, aerobic exercise, or Beta-2 agonist treatment.
Follow their assigned regimen for 4 weeks. Provide tissue samples from the dorsocervical area and abdomen before and after the 4-week intervention.
Undergo analysis of these samples using advanced techniques to understand the presence and activity of brown and beige fat cells.
Comparison Group: Researchers will compare the effects of different interventions (thermoneutral exposure, cold exposure, aerobic exercise, Beta-2 agonist treatment) on the presence and thermogenesis of brown and beige fat cells in the dorsocervical area.

开始日期2024-11-01

申办/合作机构

Universidad de Almería

[+2]

100 项与硫酸沙丁胺醇相关的临床结果

登录后查看更多信息

100 项与硫酸沙丁胺醇相关的转化医学

登录后查看更多信息

100 项与硫酸沙丁胺醇相关的专利（医药）

登录后查看更多信息

11,104

项与硫酸沙丁胺醇相关的文献（医药）

2025-02-01·CLINICAL NEUROPHYSIOLOGY

Experience with salbutamol treatment in a family with congenital myasthenia due to CHRNE mutation

Letter

作者: Khojakulov, Zakhiriddin ; Başak, Ayşe Nazlı ; Kızılkılıç, Esra Koçhan ; Demirbilek, Veysi ; Erener, Nursena ; Tezen, Didem

2025-01-01·NEUROMUSCULAR DISORDERS

CHRNE-related congenital myasthenic syndrome in Iran: Clinical and molecular insights

Article

作者: Nafissi, Shahriar ; Ziaadini, Bentolhoda ; Karimi, Narges ; Panahi, Akram ; Ghasemi, Aida

Variants in the CHRNE gene can lead to a condition called congenital myasthenic syndrome (CMS), which affects the neuromuscular junction (NMJ). CHRNE mutations are the most common cause of CMS. Seventy-seven patients with a possible diagnosis of CMS were referred to the neuromuscular clinic of Shariati Hospital affiliated with the Tehran University of Medical Sciences. We performed whole-exome sequencing (WES) to determine the underlying defect in a group of individuals with a possible diagnosis of CMS. Clinical features and morphological and molecular data on 33 patients with mutations in CHRNE were described. Age of onset, age at diagnosis, consanguinity, family history, motor milestone delay, ophthalmoparesis, generalized fatigue, dysphagia, neurophysiologic findings, and response to treatment of the patients were assessed. Nineteen CHRNE variants including 10 novel ones were identified. The most common mutations were c.1327del; (p.Glu443LysfsTer64) in four different families and c.1252-1267dup; (p.Cys423SerfsTer38) in three families. Clinical onset was mostly at birth or under one year with bilateral fatigable ptosis, ophthalmoplegia, bulbar weakness, and proximal muscle weakness. All patients were treated with pyridostigmine ± salbutamol, which resulted in improvement of motor function, dysphagia, and breathing.

2025-01-01·JOURNAL OF ETHNOPHARMACOLOGY

Evidence to support cultivated fruiting body of Ophiocordyceps sinensis (Ascomycota)'s role in relaxing airway smooth muscle

Article

ETHNOPHARMACOLOGICAL RELEVANCE:

Ophiocordyceps sinensis (O. sinensis) is a genus of Ascomycete fungus that is endemic to the alpine meadows of the Tibetan Plateau and adjoining Himalayas. It has been used traditionally as a tonic to improve respiratory health in ancient China as well as to promote vitality and longevity. Bioactive components found in O. sinensis such as adenosine, cordycepin, 3-deoxyadenosine, L-arginine and polysaccharides have gained increasing interest in recent years due to their antioxidative and other properties, which include anti-asthmatic, antiviral, immunomodulation and improvement of general health.

AIM OF THE STUDY:

This study's primary aim was to investigate the effect of a cultivated fruiting body of O. sinensis strain (OCS02®) on airways patency and the secondary focus was to investigate its effect on the lifespan of Caenorhabditis elegans.

MATERIALS AND METHODS:

A cultivated strain, OCS02®, was employed and the metabolic profile of its cold-water extract (CWE) was analysed through liquid chromatography-mass spectrometry (LC-MS). Organ bath approach was used to investigate the pharmacological properties of OCS02® CWE when applied on airway tissues obtained from adult male Sprague-Dawley rats. The airway relaxation mechanisms of OCS02® CWE were explored using pharmacological tools, where the key regulators in airway relaxation and constriction were investigated. For the longevity study, age-synchronised, pos-1 RNAi-treated wild-type type Caenorhabditis elegans at the L4 stage were utilised for a lifespan assay.

RESULTS:

Various glycopeptides and amino acids, particularly a high concentration of L-arginine, were identified from the LC-MS analysis. In airway tissues, OCS02® CWE induced a significantly greater concentration-dependent relaxation when compared to salbutamol. The relaxation response was significantly attenuated in the presence of NG-Nitro-L-arginine methyl ester (L-NAME), 1H-[1,2,4]oxadiazolo [4,3-a]quinoxalin-1-one (ODQ) and several K⁺ channel blockers. The longevity effect induced by OCS02® CWE (5 mg/mL and above) was observed in C. elegans by at least 17%.

CONCLUSIONS:

These findings suggest that the airway relaxation mechanisms of OCS02® CWE involved cGMP-dependent and cGMP-independent nitric oxide signalling pathways. This study provides evidence that the cultivated strain of OCS02® exhibits airway relaxation effects which supports the traditional use of its wild O. sinensis in strengthening respiratory health.

211

项与硫酸沙丁胺醇相关的新闻（医药）

2024-12-23

·Endpoints

Federal appeals court says Teva must delist Orange Book inhaler patents

The Federal Trade Commission is praising an appeals court decision calling for Teva to delist five inhaler patents from the FDA’s Orange Book. The case relates to Amneal’s efforts to market a generic version of Teva’s ProAir HFA, an albuterol-based inhaler product that can be used to treat breathing difficulties. It’s also a win for the FTC, which challenged the same patents last year during its campaign against what it says are improperly listed patents in the FDA’s database. Hannah Garden-Monheit, director of the FTC’s Office of Policy Planning, said in a news release on Friday that the appellate decision “sets the stage for removal of junk listings on a range of other critical medications where junk device listings impede competition.” The patents in question cover aspects of ProAir HFA’s metered dose-counting mechanism. A New Jersey federal judge ruled in October that the patents are not properly listed because they don’t meet a key requirement that involves claiming the actual drug, in this case albuterol sulfate. A federal appeals court agreed, opining on Friday that “patents claiming just the device components of the product approved in an NDA do not meet the listing requirement of claiming the drug for which the applicant submitted the application.” A Teva spokesperson told Endpoints News on Monday that the company “disagrees with the decision,” and is “reviewing next steps.” The FTC has challenged hundreds of Orange Book patents, arguing that they can lead to unjust delays for lower-cost generics.

2024-12-17

·摩熵医药

山东新时代丰收！入局首款2亿畅销药，28款重磅品种过评，13款1类新药……

注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需要得到授权。 12月17日，据CDE官网最新公示，山东新时代药业提交的4类仿制托吡酯片上市申请获受理，该品种是一款畅销抗癫痫药。目前，有13款新药获批临床。今年以来，公司已有28个品种获批过评。截图来源：CDE 2亿畅销抗癫痫药，多家药企抢国产第4家托吡酯片原研是西安杨森，于2003年在中国上市。该品种是一种新型广谱抗癫痫药物，主要用于初诊为癫痫的患者的单药治疗或曾经合并用药现转为单药治疗的癫痫患者，也可用于成人及2-16岁儿童部分性癫痫发作的加用治疗。据摩熵医药数据库显示，该品种在2023年全国医院(全终端)市场的销售总额逼近2亿元。截图来源：摩熵医药（原药融云）全国医院销售(全终端)数据库目前，托吡酯片在国内仅有西安杨森制药、浙江华海药业以及安徽杰玺医药获得批文。在仿制药布局方面，除山东新时代药业，托吡酯片在国内还有海南日中天制药、四川科瑞德制药、上海理想制药提交了4类仿制申请，均在审评审批中。目前，山东新时代药业在抗癫痫药领域尚未有产品获批，而托吡酯片是公司首款入局的抗癫痫药，无疑将为公司开辟一片全新的市场蓝海，带来前所未有的发展机遇。截图来源：摩熵医药（原药融云）中国药品审评数据库 28款品种重磅过评，13款1类新药IND获批近日，据NMPA官网公示，山东新时代药业提交的3款4类仿制药硝苯地平控释片、异氟烷、吸入用硫酸沙丁胺醇溶液同日获批。今年以来，山东新时代药业（含鲁南贝特制药）已有28个品种获批并过评，其中有异氟烷、酒石酸托特罗定片、阿昔莫司胶囊3款为首家品种。在这些获批并过评的品种中，片剂和注射剂的数量最多，各占11款，进一步丰富了公司的产品线。截图来源：摩熵医药（原药融云）过评药品汇总数据库今年以来，山东新时代药业在创新研发领域取得持续进展，申报IND的有4款1类新药（洛奈利单抗注射液、LNF2008单抗、LNF2007双抗、重组人源化抗BCMA/CD3双抗）及2款改良新药、2款生物类似药。目前，公司（含鲁南贝特制药）有13款1类新药获批临床，涉及神经系统药物、抗肿瘤药和免疫机能调节药物、心血管系统药物等治疗领域。截图来源：摩熵医药（原药融云）中国药品审评数据库在仿制药布局方面，目前山东新时代药业提交了41款品种的仿制申请，其中比拉斯汀口崩片、盐酸纳呋拉啡口崩片、盐酸环苯扎林缓释胶囊、布瑞哌唑口崩片4款药物暂无国内药企获批，山东新时代药业将与多家企业竞争国内首仿。结语山东新时代药业在近期的发展中取得了显著成果。公司入局首款畅销抗癫痫药市场，28款品种获批过评，13款1类新药获批进入临床阶段。在仿制药领域，公司同样表现不俗，提交了41款品种的仿制申请，并4款药物有望竞争国内首仿的地位。这些成绩的取得，不仅彰显了公司强大的研发实力和市场竞争力，也为公司的未来发展奠定了坚实的基础。 END 本文为原创文章，转载请留言获取授权近期热门资源获取后台回复关键词“深度报告”，获取价值18600元，报告大礼包后台回复关键词“2023首仿”，获取2023年首仿药物获批名单后台回复“GLP-1深度报告”，获取完整《GLP-1产业现状与未来发展》PDF版。后台回复“中国 I 类新药”，获取完整《中国 I 类新药靶点》PDF版。后台回复“NAFLD/NASH”，获取完整《NAFLD/NASH报告》PDF版。后台回复“AI+制药”，获取完整《中国AI制药企业白皮书》PDF版。后台回复“XXG”，获取完整《中国心血管系统药物分析报告》PDF版。后台回复“FZZJ”，获取完整《基于剂型改良的复杂注射剂分析》PDF版。后台回复“药品进出口”，获取完整《中国药品进出口白皮书》深度报告-PDF版。联系我们，体验摩熵医药更多专业服务会议合作园区服务数据库咨询定制服务媒体合作 👆👆👆点击上方图片，即可开启摩熵化学数据查询点击阅读原文，申请摩熵医药企业版免费试用！

临床申请生物类似药上市批准医药出海

2024-12-11

·GlobeNewswire-Health Care

Teva Announces New Patient Access Program with Direct Relief to Provide Access to Inhalers for Uninsured Patients

Teva to provide two generic inhaler products to Direct Relief for its network of free and charitable clinicsThe program, launching this month, will run for a minimum of three years PARSIPPANY, N.J., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the launch of a new patient access program, in partnership with Direct Relief, to supply inhalers to eligible patients in the United States free of charge. “In the United States, while 93% of Teva’s inhaler medicines are generic products with access at lower prices – particularly for insured patients – there still remain uninsured patients who cannot access affordable generic inhalers,” said Chris Fox, Executive Vice President, U.S. Commercial at Teva. “The aim of this program is to help address an unmet need in underserved communities nationwide, enhancing patient access to safe and affordable medicines delivered via inhalers, including both maintenance and rescue inhalers.” Teva will make two inhaler products available through this program: generic versions of the AirDuo®RespiClick® (fluticasone propionate/salmeterol xinafoate maintenance inhaler) and ProAir® HFA (albuterol sulfate rescue inhaler). Teva will donate the inhalers to Direct Relief for distribution by request to free & charitable clinics, to then be dispensed to uninsured patients served by these clinics. "Direct Relief is deeply grateful to Teva for this critical donation which will connect patients with respiratory treatments they otherwise would not have access to," said Katie Lewis, Regional Director, U.S. Programs for Direct Relief. "Free and charitable clinics offer quality care for underserved communities, and this donation will allow them to reach even more patients with these medications." The program will continue for a minimum of three years to ensure reliable and continuous supply to these patients. In addition to donating the inhalers, Teva will make a cash donation to Direct Relief to cover the costs of administering this program. Direct Relief, Teva’s long-time partner on access to medicines programs in the U.S. and around the world, is a nonprofit humanitarian organization that provides medical resources to resource-poor communities. It operates, by its own account, the largest charitable medicine program in the United States. Through its network, Direct Relief supports the dispensing of high-quality, no-cost medicines to low-income, uninsured patients at the point of care, thereby facilitating patient access to necessary medicines. About Teva Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a global pharmaceutical leader with a category-defying portfolio, harnessing our generics expertise and stepping up innovation to continue the momentum behind the discovery, delivery, and expanded development of modern medicine. For over 120 years, Teva's commitment to bettering health has never wavered. Today, the company’s global network of capabilities enables its ~37,000 employees across 58 markets to push the boundaries of scientific innovation and deliver quality medicines to help improve health outcomes of millions of patients every day. To learn more about how Teva is all in for better health, visit www.tevapharm.com. Cautionary Note Regarding Forward-Looking Statements This document and the presentation at the conference may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our to successfully make our two inhaler products available through the new patient access program; our ability to successfully compete in the marketplace including our ability to successfully execute our Pivot to Growth strategy; our substantial indebtedness; our business and operations in general including the impact of global economic conditions and other macroeconomic developments and the governmental and societal responses thereto; compliance, regulatory and litigation matters; other financial and economic risks; and other factors discussed in our Quarterly Report on Form 10-Q for the third quarter of 2024 and in our Annual Report on Form 10-K for the year ended December 31, 2023, including in the sections captioned "Risk Factors.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements. IR Contacts TevaIR@Tevapharm.com PR Contacts United States Kelley Dougherty (973) 658-0237 Israel Yonatan Beker Eden Klein (973) 264 7378 972 (3) 906-2645

100 项与硫酸沙丁胺醇相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	硫酸沙丁胺醇	R03CC02 R03AC02	DB01001

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
运动诱发哮喘	美国	Schering Corp.	1981-05-01
支气管痉挛	美国	Schering Corp.	1981-05-01
气道阻塞	日本	GSK Plc	1973-01-13
哮喘	日本	GSK Plc	1973-01-13
支气管炎	日本	GSK Plc	1973-01-13
肺气肿	日本	GSK Plc	1973-01-13
肺结核	日本	GSK Plc	1973-01-13

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
急性哮喘	申请上市	加拿大	益得生物科技股份有限公司	-
持续性哮喘	临床3期	美国	Teva Branded Pharmaceutical Products R&D, Inc.	2012-12-01
儿童哮喘	临床3期	美国	Teva Branded Pharmaceutical Products R&D, Inc.	2006-06-10
慢性阻塞性肺疾病	临床3期	美国	GSK Plc	2004-09-01
慢性阻塞性肺疾病	临床3期	波多黎各	GSK Plc	2004-09-01
特发性肺纤维化	临床1期	英国	GSK Plc	2012-04-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04276233 (PRISM, CTgov)	临床4期	哮喘 \| 嗜酸性粒细胞性哮喘	100	Mepolizumab	膚鹹憲願顧鹹鏇鏇繭願(簾壓膚餘壓製憲窪窪鑰) = 築廠範獵艱齋繭觸膚構鏇範顧壓糧顧鬱願餘築 (憲膚糧觸遞觸願夢鑰糧, 蓋窪築顧憲遞積製選選 ~ 廠壓製鬱願齋鑰遞範網) 更多	-	2024-12-10
NCT03199976 (CTgov)	临床4期	哮喘 \| 气道阻塞 \| 喘息性支气管炎	80	Tiotropium Bromide+salbutamol (Tiotropium Bromide & Salbutamol)	簾廠廠廠憲壓願觸夢醖(餘顧憲艱餘顧觸醖遞積) = 窪積鏇夢鹽鏇襯壓網顧廠鹽築築繭衊膚憲艱鹽 (淵襯願壓遞壓憲網鹽繭, 齋壓網積壓艱壓觸窪簾 ~ 憲獵憲範淵鹹遞廠鬱夢) 更多	-	2024-09-19
				salbutamol+Fluticasone Propionate (Fluticasone Propionate & Salbutamol)	簾廠廠廠憲壓願觸夢醖(餘顧憲艱餘顧觸醖遞積) = 廠願衊構夢顧網糧壓簾廠鹽築築繭衊膚憲艱鹽 (淵襯願壓遞壓憲網鹽繭, 夢製網顧醖願醖醖顧願 ~ 鬱淵遞鏇網夢糧糧願衊) 更多
ATS2024	N/A	-	-	Albuterol pMDI alone	構遞夢壓糧廠艱糧壓壓(艱淵餘獵鏇製憲選鹹膚) = 餘積鹹壓積蓋鑰選壓窪憲觸齋鹽鏇齋願願夢構 (齋醖蓋醖蓋選鑰製窪餘, 32 ~ 39)	-	2024-05-19
				Albuterol pMDI + VHC	構遞夢壓糧廠艱糧壓壓(艱淵餘獵鏇製憲選鹹膚) = 鏇鹹鏇壓窪餘獵網鏇衊憲觸齋鹽鏇齋願願夢構 (齋醖蓋醖蓋選鑰製窪餘, 1.1 ~ 1.7)
NCT02508311 (CTgov)	临床4期	呼吸麻痹 \| 脊髓损伤	1	Oral Albuterol Extended Release (Active Oral Beta-2)	網膚鏇衊膚蓋壓夢網範(鹽遞淵簾網膚築製積膚) = 糧觸艱廠顧繭鹽鏇衊鑰鑰壓鬱遞鑰齋襯獵憲網 (簾顧願製願獵構齋遞願, 襯餘繭顧糧蓋願壓簾餘 ~ 鹽蓋壓顧鬱鹹顧鬱遞觸) 更多	-	2024-05-07
				Placebo (Placebo)	網膚鏇衊膚蓋壓夢網範(鹽遞淵簾網膚築製積膚) = 觸選憲憲醖齋淵觸鑰鬱鑰壓鬱遞鑰齋襯獵憲網 (簾顧願製願獵構齋遞願, 願壓廠築範獵蓋淵淵廠 ~ 淵齋淵壓範網獵願觸顧) 更多
NCT00521222 (ARGARG, CTgov)	N/A	哮喘	90	Albuterol HFA+Ipratropium HFA+Fluticasone (Arg/Arg Genotype on Advair (Fluticasone With Salmeterol) HFA)	鹽鹹糧鹽襯艱鏇醖齋觸(願構餘艱蓋遞簾鑰鹽糧) = 艱構鹹襯廠繭憲餘網鑰壓襯積衊鹹獵憲壓構鑰 (築壓夢糧範襯膚網壓築, 衊觸憲鑰蓋顧積鏇鏇顧 ~ 夢願鬱糧廠範壓淵鹹選) 更多	-	2023-04-21
				Albuterol HFA+Ipratropium HFA+Fluticasone (Gly/Gly Genotype on Advair (Fluticasone With Salmeterol) HFA)	鹽鹹糧鹽襯艱鏇醖齋觸(願構餘艱蓋遞簾鑰鹽糧) = 淵夢廠獵蓋壓顧築選餘壓襯積衊鹹獵憲壓構鑰 (築壓夢糧範襯膚網壓築, 範糧鹽膚齋獵襯餘製鏇 ~ 憲鏇鹽醖選窪鹽淵膚壓) 更多
NCT04677959 (CONNECT2, CTgov)	临床4期	哮喘	427	Albuterol+Fluticasone propionate/salmeterol (FS)	廠糧壓網糧網艱艱範醖(選遞顧鹹鑰鑰鬱選繭鹹) = 遞觸蓋鏇遞鬱簾憲窪網夢襯遞夢鬱顧膚築構餘 (窪鬱觸鹽廠遞餘夢齋膚, 壓築網鏇鏇齋選顧鹹範 ~ 膚製艱構蓋鹹襯繭醖選) 更多	-	2023-03-14
NCT03890666 (CONNECT1, CTgov)	临床4期	哮喘	333	albuterol (Concurrent Control (CC))	鹽餘鹽窪壓願艱顧範齋(夢壓窪網窪餘齋淵壓網) = 淵淵獵觸構鏇膚鬱觸膚蓋構遞窪醖製鬱襯鑰鹹 (餘淵窪積蓋築糧積觸選, 廠遞觸餘製膚蓋獵鑰遞 ~ 簾齋簾鹹憲選觸選餘醖) 更多	-	2022-10-27
				Albuterol eMDPI DS (Digital System (DS))	鹽餘鹽窪壓願艱顧範齋(夢壓窪網窪餘齋淵壓網) = 積構範壓簾膚願網壓壓蓋構遞窪醖製鬱襯鑰鹹 (餘淵窪積蓋築糧積觸選, 鏇壓築糧憲壓範簾齋範 ~ 鹹簾衊構獵遞鹹淵餘醖) 更多
ERS2022	N/A	心血管疾病	-	Salbutamol	範簾餘築廠夢鏇膚構鏇(積鑰鏇選衊遞餘鬱糧齋) = Salbutamol was associated with a very common risk of palpitations or tachycardia, suggesting more clinical vigilance 糧願顧鏇夢網夢簾獵窪 (觸齋積遞築襯齋艱齋廠 )	不佳	2022-09-04
ERS2022	N/A	慢性阻塞性肺疾病	58	Salbutamol	遞願獵蓋鏇齋遞艱膚蓋(糧壓夢積艱願齋餘齋廠) = 繭淵鑰蓋艱網遞淵餘構蓋窪遞壓願艱觸鏇襯壓 (觸網簾艱鏇廠顧範鏇廠 ) 更多	积极	2022-09-04
				Salbutamol	遞願獵蓋鏇齋遞艱膚蓋(糧壓夢積艱願齋餘齋廠) = 淵壓膚鏇糧衊構觸夢願蓋窪遞壓願艱觸鏇襯壓 (觸網簾艱鏇廠顧範鏇廠 ) 更多
NCT00530062 (CTgov)	临床4期	哮喘	49	Albuterol-HFA-BAI (Albuterol-HFA-BAI)	選積鏇簾淵遞簾夢淵餘(齋積願繭遞構選鹽膚廠) = 廠繭壓憲艱觸積觸觸壓鏇醖膚襯壓餘構顧繭鑰 (網蓋選淵繭夢顧醖壓鹹, 憲簾齋獵鹹糧齋觸餘簾 ~ 夢窪醖糧夢鏇網廠鏇淵) 更多	-	2022-08-31
				Albuterol-HFA-MDI (Albuterol-HFA-MDI)	選積鏇簾淵遞簾夢淵餘(齋積願繭遞構選鹽膚廠) = 選願鬱蓋艱遞襯鏇蓋鹽鏇醖膚襯壓餘構顧繭鑰 (網蓋選淵繭夢顧醖壓鹹, 選艱鬱鏇壓遞窪構築顧 ~ 淵壓夢築蓋餘窪蓋遞觸) 更多